Verona Pharma plc: directors' dealings · United States · SEC (Form 4)

About Verona Pharma plc

Verona Pharma plc is a biopharmaceutical company listed on the Nasdaq market in the United States (United States), with a focused strategy in chronic respiratory disease. The company was built around ensifentrine, a proprietary inhaled molecule that Verona describes as a dual PDE3/PDE4 inhibitor with both bronchodilator and non-steroidal anti-inflammatory properties. Its flagship commercial asset is Ohtuvayre® (ensifentrine), which received FDA approval in June 2024 for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. That approval marked a major inflection point in Verona’s corporate development, shifting the company from a clinical-stage respiratory specialist toward a commercial-stage growth story. Historically, Verona Pharma developed its respiratory franchise through research and clinical programs centered on inhaled therapies for COPD and other chronic lung conditions. The company’s operational footprint has been anchored in London and Raleigh, North Carolina, reflecting its UK heritage and its US commercialization base. Verona’s business model is now primarily driven by the US launch and uptake of Ohtuvayre, supported by a specialty-pharmacy distribution model and a commercial strategy aimed at pulmonologists and other key prescribers. Management has repeatedly emphasized the sizeable unmet medical need in COPD, a disease that remains highly prevalent and often symptomatic despite existing maintenance therapies. From a competitive standpoint, Verona Pharma operates in a crowded respiratory-pharma landscape dominated by large multinational drugmakers and established COPD franchises. Its main differentiator is the novelty of ensifentrine’s mechanism and its inhaled profile, which may position Ohtuvayre as a distinct maintenance option if real-world adoption and reimbursement trends remain favorable. The company has also discussed lifecycle opportunities around ensifentrine, including dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations, as well as a fixed-dose combination with glycopyrrolate. Beyond COPD, Verona has outlined exploratory development opportunities in asthma, bronchiectasis, and cystic fibrosis, all of which fit its broader respiratory expertise. Geographically, the company’s commercial focus is overwhelmingly the United States, while ex-US opportunities have been pursued through strategic partnerships, including a collaboration with Nuance Pharma in Greater China. Recent highlights include FDA approval in 2024, the US commercial launch in 2024, and 2025 reporting that showed strong early sales momentum for Ohtuvayre. Verona also disclosed a 2025 acquisition agreement with Merck, underscoring the strategic value of its respiratory platform and commercial asset. For investors tracking VRNA, the Nasdaq listing in the United States places Verona at the intersection of specialty pharma innovation, launch execution, and potential strategic M&A value creation.